Significant Anti-Cancer Effect Observed in Studies
Filed with ASX · · 3 pages · English
• Positive results provide support for Zelda to continue its programme of study evaluating its THC-rich medical cannabis formulations as anti-cancer therapeutics Specifically, this initial study compared the anti-tumour responses of pure tetrahydrocannabinol (THC) versus the Zelda Therapeutics formulation of THC-rich oil and at the same time compare the potency against a standard chemotherapy drug
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- Zelda expands its Intellectual Property portfolio
- OpenBriefing Recording with Dr Stewart Washer
- Reinstatement to Official Quotation - 22 November 2016
- Suspension from Official Quotation
- Prospectus
Later from Zelira Therapeutics
- Collaboration Agreement with Telethon Kids Institute
- Sleep Disorder Clinical Trials Update
- Zelda to Test Formulations Against Pancreatic Cancer
- Quarterly Report and Appendix 4C
- Appendix 4D & FY17 Interim Financial Report
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics